Anamorelin, a ghrelin receptor agonist, was applied to treat patients with non-small cell lung cancer (NSCLC) and cachexia–anorexia to enhance appetite and anabolic activity in clinical phase III (Garcia et al., 2015; Currow et al., 2017). The gene discussed is GHSR; the disease is non-small cell lung carcinoma.